2013 Fiscal Year Final Research Report
Resistance mechanisms for anti-tubulin agents in malignant melanomas
Project/Area Number |
24791171
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Multi-year Fund |
Research Field |
Dermatology
|
Research Institution | Iwate Medical University |
Principal Investigator |
AKASAKA K 岩手医科大学, 医学部, 研究員 (90552753)
|
Project Period (FY) |
2012-04-01 – 2014-03-31
|
Keywords | 悪性黒色腫 / BCL2 / BCLxL / 抗微小管薬 |
Research Abstract |
Previous studies have suggested a link between TUBB3 overexpression and paclitaxel resistance through alterations in the properties of the mitotic spindle. We found that paclitaxel treatment induced temporary mitotic arrest in 7 melanoma cell lines irrespective of the TUBB3 level, suggesting that TUBB3 had no significant influence on spindle properties. On the other hand, the amount of BCL2, an anti-apoptotic protein, was well correlated with paclitaxel resistance. Treatment of the paclitaxel-resistant cell lines with ABT-737, an inhibitor of BCL2 and BCLxL, or simultaneous knock-down of BCL2 and BCLxL dramatically increased the cells' sensitivity, while knock-down of MCL1, another member of the BCL2 family, had only a minimal effect. Our results suggest that the paclitaxel sensitivity of melanoma cells is attributable to apoptosis susceptibility rather than a change in spindle properties and that BCL2 and BCLxL play a pivotal role in the former.
|
-
-
-
[Journal Article] Transcriptional and post-transcriptional regulation of βIII-tubulin protein expression in relation with cell cycle-dependent regulation of tumor cells2012
Author(s)
Shibazaki M, Maesawa C, Akasaka K, Kasai S, Yasuhira S, Kanno K, Nakayama I, Sugiyama T, Wakabayasi G, Masuda T, Mori N
-
Journal Title
Int J Oncol
Volume: 40(3)
Pages: 695-702
DOI
-